4H-1-Benzopyran-4-one, 7,8-bis[[(methylamino)carbonyl]oxy]-2-phenyl- manufacturers
- TrkB-IN-1
-
-
2026-05-11
- CAS:1609067-49-3
- Purity:
- Supply Ability: 10g
|
| | 4H-1-Benzopyran-4-one, 7,8-bis[[(methylamino)carbonyl]oxy]-2-phenyl- Basic information |
| | 4H-1-Benzopyran-4-one, 7,8-bis[[(methylamino)carbonyl]oxy]-2-phenyl- Chemical Properties |
| Boiling point | 545.7±50.0 °C(Predicted) | | density | 1.353±0.06 g/cm3(Predicted) | | solubility | Acetonitrile: Slightly soluble: 0.1-1 mg/ml
DMSO: Slightly soluble: 0.1-1 mg/ml
Water: Slightly soluble: 0.1-1 mg/ml | | pka | 11.22±0.46(Predicted) |
| | 4H-1-Benzopyran-4-one, 7,8-bis[[(methylamino)carbonyl]oxy]-2-phenyl- Usage And Synthesis |
| Uses | TrkB-IN-1 is a potent and orally active TrkB agonist and has favorable PK properties. TrkB-IN-1 reverses the cognitive defects in an AD mouse model and can be used for alzheimer’s disease research[1]. | | in vivo | TrkB-IN-1 (oral gavage; 7.25 mg/kg, 21.8 mg/kg, 43.6 mg/kg; 3 month) activates TrkB signaling cascade in the hippocampus of 5XFAD mice in a dose-dependent manner in 5XFAD mice, the ratio of p-TrkB/TrkB, p-Akt/Akt and p-ERK/ERK is also increased[1].
TrkB-IN-1 (oral gavage; 7.25 mg/kg, 21.8 mg/kg, 43.6 mg/kg; 5 days) alleviates Aβ deposition and rescues memory deficits in 5XFAD mice[1].
TrkB-IN-1 (oral gavage; 36 mg/kg) exhibits ～10.5% oral bioavailability with a Cmaxof 129 ng/mL, Tmaxof 0.5 h, and T1/2for oral administration of 3.66 h[1]. | | IC 50 | TrkB | | References | [1] Chun Chen, et al. The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer's disease. Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):578-583. DOI:10.1073/pnas.1718683115 |
| | 4H-1-Benzopyran-4-one, 7,8-bis[[(methylamino)carbonyl]oxy]-2-phenyl- Preparation Products And Raw materials |
|